文献速递安宁疗护认知障碍与谵妄多重用药

生命末期养老院退伍军人他汀停药情况分析

Discontinuation of Statins in Veterans Admitted to Nursing Homes near the End of Life.
PubMed 文献 · J Am Geriatr Soc · 2020-08-12

该回顾性队列研究纳入2009至2015财年入住VA养老院且符合有限预期寿命或晚期痴呆标准的65岁以上退伍军人共13110例,分析他汀停药预测因素。结果显示第91天累积停药发生率为31%,有临终状态标注或使用临终关怀者停药率(52%)明显高于无此标注者(25%)。

要点

  • 第91天他汀累积停药发生率为31%(95%CI 30%-32%)。
  • 有临终状态标注或使用临终关怀者停药率52%,无者为25%。
  • 多数有限预期寿命或晚期痴呆患者入住后并未停用他汀。

核心结论

  • 多数因二级预防服用他汀的有限预期寿命或晚期痴呆退伍军人入住社区生活中心后未停用他汀。
  • 标注临终状态、使用临终关怀及提示预后不良的个体临床因素可能促成处方精简。

研究设计与样本

  • 回顾性队列研究,链接VA条形码用药记录、最小数据集评估和利用记录与Medicare索赔数据。
  • 纳入2009至2015财年入住VA社区生活中心的65岁以上退伍军人,共13110例。

主要发现

  • 第91天他汀停药累积发生率为31%(95%CI 30%-32%)。
  • 有临终状态标注或使用临终关怀者停药率为52%(95%CI 50%-55%),无者为25%(95%CI 24%-26%)。
  • 在有临终状态标注或使用临终关怀者中,肥胖、充血性心力衰竭和非医院来源入院预测停药可能性降低。
  • 在有临终状态标注或使用临终关怀者中,晚期痴呆、日常生活活动依赖、用药数量多和地理区域预测停药可能性增加。
  • 在无临终状态标注或使用临终关怀者中,年龄较大和若干特定预后不良标志预测停药增加,肥胖或超重预测停药减少。

临床怎么用

  • 对有限预期寿命或晚期痴呆的二级预防他汀使用者,可考虑结合临终状态标注、临终关怀使用及预后不良因素进行处方精简评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Geriatric guidelines recommend against statin use in older adults with limited life expectancy (LLE) or advanced dementia (AD). This study examined resident and facility factors predicting statin discontinuation after nursing home (NH) admission in veterans with LLE/AD taking statins for secondary prevention. DESIGN: Retrospective cohort study of Veterans Affairs (VA) bar code medication administration records, Minimum Data Set (MDS) assessments, and utilization records linked to Medicare claims. SETTING: VA NHs, known as community living centers (CLCs). PARTICIPANTS: Veterans aged 65 and older with coronary artery disease, stroke, or diabetes mellitus, type II, admitted in fiscal years 2009 to 2015, who met criteria for LLE/AD on their admission MDS and received statins in the week after admission (n = 13,110). MEASUREMENTS: Residents were followed until statin discontinuation (ie, gap in statin use ≥14 days), death, or censoring due to discharge, day 91 of the stay, or end of the study period. Competing risk models assessed cumulative incidence and predictors of discontinuation, stratified by whether the resident had their end-of-life (EOL) status designated or used hospice at admission. RESULTS: Overall cumulative incidence of statin discontinuation was 31% (95% confidence interval [CI] = 30%-32%) by day 91, and it was markedly higher in those with (52%; 95% CI = 50%-55%) vs without (25%; 95% CI = 24%-26%) EOL designation/hospice. In patients with EOL designation/hospice (n = 2,374), obesity, congestive heart failure, and admission from nonhospital settings predicted decreased likelihood of discontinuation; AD, dependency in activities of daily living, greater number of medications, and geographic region predicted increased likelihood of discontinuation. In patients without EOL designation/hospice (n = 10,736), older age and several specific markers of poor prognosis predicted greater discontinuation, whereas obesity/overweight predicted decreased discontinuation. CONCLUSION: Most veterans with LLE/AD taking statins for secondary prevention do not discontinue statins following CLC admission. Designating residents as EOL status, hospice use, and individual clinical factors indicating poor prognosis may prompt deprescribing.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Thorpe CT, Sileanu FE, Mor MK, et al. Discontinuation of Statins in Veterans Admitted to Nursing Homes near the End of Life. J Am Geriatr Soc. 2020. PMID: 32786004. doi:10.1111/jgs.16727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。